Valve Academic Research Consortium Consensus Report
نویسندگان
چکیده
منابع مشابه
Mitral Valve Academic Research Consortium consensus report: the U.S. Food and Drug Administration perspective.
This editorial refers to ‘Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles’, by G.W. Stone et al., on page 1851 and ‘Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions’, by G.W. Stone et al., on page 1...
متن کاملStandardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium†
OBJECTIVES To propose standardized consensus definitions for important clinical endpoints in transcatheter aortic valve implantation (TAVI), investigations in an effort to improve the quality of clinical research and to enable meaningful comparisons between clinical trials. To make these consensus definitions accessible to all stakeholders in TAVI clinical research through a peer reviewed publi...
متن کاملUpdated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2).
OBJECTIVES The aim of the current Valve Academic Research Consortium (VARC)-2 initiative was to revisit the selection and definitions of transcatheter aortic valve implantation (TAVI) clinical endpoints to make them more suitable to the present and future needs of clinical trials. In addition, this document is intended to expand the understanding of patient risk stratification and case selectio...
متن کاملStandardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
Roxana Mehran, MD; Sunil V. Rao, MD; Deepak L. Bhatt, MD, MPH; C. Michael Gibson, MS, MD; Adriano Caixeta, MD, PhD; John Eikelboom, MD, MBBS; Sanjay Kaul, MD; Stephen D. Wiviott, MD; Venu Menon, MD; Eugenia Nikolsky, MD, PhD; Victor Serebruany, MD, PhD; Marco Valgimigli, MD, PhD; Pascal Vranckx, MD; David Taggart, MD, PhD; Joseph F. Sabik, MD; Donald E. Cutlip, MD; Mitchell W. Krucoff, MD; E. M...
متن کاملThe pulmonary hypertension academic research consortium
The search for effective treatments for pulmonary hypertension (PH) has been frustrating. The very first drug for idiopathic pulmonary arterial hypertension (PAH), epoprostenol, was approved in 1995.[1] And while progress has been made, a look at where we were, where we are, and where we need to be suggests we are far from accomplishing our goals.[2] We have identified three classes of drugs th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2011
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2011.02.070